Ronald P. Karlsberg MD FACP FAHA FACC MSCCT |

Tirzepatide Moves Beyond Diabetes and Weight Loss: A New Cardiovascular Indication

Tirzepatide (Mounjaro) has taken an important step forward in cardiovascular prevention. Mounjaro is now FDA approved to reduce the risk of major adverse cardiovascular events—cardiovascular death,